Announcement on Voluntary Disclosure of Inclusion of Gecacitinib Hydrochloride Tablets in the 2025 National Medical Insurance Drug Catalog

About this update from Suzhou Zelgen Biopharmaceuticals Co. Ltd. Class A

Announcement on Voluntary Disclosure of Inclusion of Gecacitinib Hydrochloride Tablets in the 2025 National Medical Insurance Drug Catalog The abstract is for reference only. Please refer to the full text of the announcement on the very day. Link of Full Text for Reference: View Attachment

View stock analysis, news, and events for Suzhou Zelgen Biopharmaceuticals Co. Ltd. Class A